2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 997

Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Abstract Number: 2670

Does Change In Femorotibial Cartilage Thickness Differ Between Acutely Anterior-Cruciate Ligament Injured Knees Treated With and Without Reconstructive Surgery
Abstract Number: 398

Does Elevated Disease Activity Or Medication Use Influence The Body Composition Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?
Abstract Number: 397

Does Elevated Disease Activity Or Medication Use Influence The Bone Density Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?
Abstract Number: 1958

Does Evaluation Of Hand Bone Loss By Digital x-Ray Radiogrammetry Within The First 3 Months After Diagnosis Of Rheumatoid Arthrits Identify Patients At Risk For Radiological Progression?
Abstract Number: 1668

Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis?
Abstract Number: 1757

Does Foot Pain Mediate The Effect Of Knee Osteoarthritis and Risk Of Indoor and Outdoor Falls In Older Men and Women?
Abstract Number: 2136

Does Functional Gain and Pain Relief After TKR and THR Differ By Patient Obese Status?
Abstract Number: 490

Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Abstract Number: 2034

Does Mixed Connective Tissue Disease Or Sharp’s Syndrome Really Exist?
Abstract Number: 515

Does Multiplex Flow Immunoassay Underdetect SSA and SSB Antibodies? An Evaluation Of The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Abstract Number: 2580

Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Abstract Number: 1359

Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Abstract Number: 2276

Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort
Abstract Number: 191

Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].